Kuca B, et al. - Researchers randomized 1856 adult subjects to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo to evaluate the efficiency and safety of lasmiditan in the acute treatment of a migraine. Participants received medication for their next migraine attack within 4 hours of onset and recorded their most bothersome symptom (MBS), which included headache pain and the presence of nausea, phonophobia, and photophobia in an electronic diary over 48 hours after dosing. They concluded more cases dosed with lasmiditan 200 mg were freed of headache pain and their MBS at 2 hours after dosing. They also observed the efficacy and well tolerance of lasmiditan dosed at 200 and 100 mg in the treatment of an acute migraine among subjects with a high level of cardiovascular risk factors.